INDIANAPOLIS, May 28, 2015 /PRNewswire/ -- Eli Lilly and
Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) will host
a webcast on June 11 to discuss data
from the first two pivotal Phase III studies of baricitinib in
rheumatoid arthritis. Data from these two trials, RA-BEACON
and RA-BUILD, will be presented on June
11 during the Scientific Programme for the EULAR Congress
2015 in Rome, Italy.
The webcast will be held from 10:00
to11:00 a.m. Eastern Daylight Time. The live audio webcast
can be accessed through a link that will be posted on the investor
sections of Lilly's and Incyte's websites. In addition, the webcast
will be available for replay through June
18, 2015.
About Baricitinib
Baricitinib is a once daily, oral, selective JAK1 and JAK2
inhibitor. There are four known JAK enzymes: JAK1, JAK2, JAK3 and
TYK2. JAK-dependent cytokines have been implicated in the
pathogenesis of a number of inflammatory and autoimmune diseases,
suggesting that JAK inhibitors may be useful for the treatment of a
broad range of inflammatory conditions. Baricitinib demonstrates
approximately 100-fold greater potency of inhibition against JAK1
and JAK2 than JAK 3 in kinase assays.
In December 2009, Lilly and Incyte
announced an exclusive worldwide license and collaboration
agreement for the development and commercialization of baricitinib
and certain follow-on compounds for patients with inflammatory and
autoimmune diseases. Baricitinib is currently in Phase III clinical
development for rheumatoid arthritis and Phase II development for
psoriasis and diabetic nephropathy.
About Baricitinib Phase III Trials
Lilly and Incyte are conducting four pivotal Phase III clinical
trials of baricitinib in patients with moderately-to-severely
active rheumatoid arthritis to support regulatory submission in
most countries. An additional Phase III study was initiated to
support clinical development in China. The clinical trial program includes a
wide range of patients including those who are methotrexate naïve,
inadequate responders to methotrexate, inadequate responders to
conventional disease-modifying anti-rheumatic drugs, or inadequate
responders to TNF inhibitors. Four of these five pivotal studies
are expected to be completed by the end of 2015. Patients
completing any of the five Phase III studies can enroll in a
long-term extension study. For additional information on this
clinical trial program, please visit www.clinicaltrials.gov.
About Incyte
Incyte Corporation is a Wilmington,
Delaware-based biopharmaceutical company focused on the
discovery, development and commercialization of proprietary
therapeutics for oncology and inflammation. For additional
information on Incyte, please visit the Company's web site at
www.incyte.com.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with
discovery to make life better for people around the world. We were
founded more than a century ago by a man committed to creating
high-quality medicines that meet real needs, and today we remain
true to that mission in all our work. Across the globe, Lilly
employees work to discover and bring life-changing medicines to
those who need them, improve the understanding and management of
disease, and give back to communities through philanthropy and
volunteerism. To learn more about Lilly, please visit us at
www.lilly.com and newsroom.lilly.com/social-channels.
(P-LLY)
This press release contains forward-looking statements about
baricitinib as a potential treatment for patients with rheumatoid
arthritis and reflects Lilly and Incyte's current beliefs. However,
as with any pharmaceutical product, there are substantial risks and
uncertainties in the process of development and commercialization.
There is no guarantee that future study results will be consistent
with study findings to-date, or that baricitinib will receive
regulatory approval. For further discussion of these and other
risks and uncertainties, see Lilly's and Incyte's filings with the
United States Securities and Exchange Commission. Lilly and Incyte
undertake no duty to update forward-looking statements.
Refer
to:
|
Celeste Stanley;
celeste_stanley@lilly.com; 317-626-8896 (Lilly media)
|
|
Phil Johnson;
johnson_philip_l@lilly.com; 317-655-6874 (Lilly
investors)
|
|
Michael Booth, DPhil;
mbooth@incyte.com; 302-498-5914 (Incyte)
|
Photo - http://photos.prnewswire.com/prnh/20031219/LLYLOGO
Photo -
http://photos.prnewswire.com/prnh/20120608/DE21226LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/lilly-and-incyte-announce-webcast-to-discuss-baricitinib-phase-iii-data-300090338.html
SOURCE Eli Lilly and Company